复星医药为控股子公司提供大额担保，累计担保金额达218亿元——投资者需关注资产负债率与风险敞口
复星医药为控股子公司提供大额担保，累计担保金额达218亿元——投资者需关注资产负债率与风险敞口
主要内容梳理
- 复星医药（600196.SH）于2026年4月10日发布公告，披露为多家控股子公司提供担保的最新进展。
- 本次涉及7家控股子公司及孙公司，担保总额为72,429万元（7.24亿元人民币）。
- 截至公告日，集团实际对外担保余额高达2,186,395万元（约218.64亿元），占2025年末公司经审计净资产的44.86%。
- 公告强调部分被担保方资产负债率超70%，反映出一定财务压力与风险敞口。
- 所有担保均在年度股东会审批额度内，无需再次提交董事会或股东会审批。
各项具体担保详情
| 被担保方 |
本次担保金额（万元） |
担保余额（万元） |
反担保安排 |
主要财务数据（2025年，万元） |
| 复星医药产业 |
38,500 |
1,008,121 |
全资子公司，无反担保 |
总资产236.65亿，净资产101.36亿，净利润6.77亿 |
| 复星健康 |
30,000 |
209,087 |
有反担保，股权质押等 |
总资产88.11亿，净资产50.42亿，净利润3,990万 |
| 徐州星晨医院 |
999 |
14,428 |
有反担保，股权质押 |
总资产4.47亿，净资产1.44亿，净利润-2,367万 |
| 天津健嘉 |
1,500 |
3,873 |
有反担保，固定资产抵押等 |
总资产2.01亿，净资产1,637万，净利润36万 |
| 济南健源 |
880 |
2,044 |
有反担保，股权质押 |
总资产2,568万，净资产2048万，净利润-1,744万 |
| 昆山健嘉 |
550 |
2,613 |
有反担保，股权质押 |
总资产1.77亿，净资产3,782万，净利润-1,100万 |
| 山东二叶 |
1,000 |
10,000 |
全资子公司，无反担保 |
总资产7.45亿，净资产3.78亿，净利润2,812万 |
担保协议主要条款
- 担保期限：以主合同项下债务履行期限届满之日起三年止，各子公司融资期限最短为36个月，最长达10年。
- 保证范围：本金、利息及其他应付费用，部分为最高额连带责任保证。
- 部分担保有反担保措施，包括股东股权质押、固定资产抵押及应收款质押等。
对投资者的重要影响与风险提示
- 大额担保或加大风险敞口： 截至2026年4月10日，集团累计对外担保金额已达218.64亿元，接近净资产的半数。大规模担保可能加大母公司整体信用风险。
- 部分被担保公司资产负债率高企： 部分被担保公司资产负债率超过70%，如遇经营不善或债务违约，母公司承担的连带责任风险显著增加。
- 部分孙公司连续亏损： 有的被担保单位近年持续亏损，如徐州星晨医院、济南健源、昆山健嘉等，短期偿债能力存疑，需持续关注其经营改善情况。
- 额度使用与后续空间： 本次担保均在年度股东会批准的3,504,800万元（350.48亿元）担保额度范围内，目前已使用额度为786,689.54万元，剩余可用额度约271.81亿元，显示集团融资及担保空间仍较为充裕。
- 无逾期担保： 截至公告日，集团无逾期担保事项。
- 董事会认同风险可控： 董事会及独立董事一致认为担保事项系经营需要，且限于控股子公司，风险相对可控。
对投资者的建议
- 建议投资者重点关注被担保公司尤其是高负债及亏损企业的经营状况变化。若亏损持续或担保企业出现违约，母公司需履行担保责任，或将对上市公司利润与现金流产生压力。
- 集团大额担保行为短中期内反映公司扩张与支持下属企业发展的经营战略，但同时加大了整体信用风险与财务压力。投资者应关注后续担保余额变化及集团对风险的管理措施。
- 如有更多担保或大额担保履行责任事件发生，或将对公司股价造成波动。
免责声明
本文仅为信息披露解读与投资参考，不构成任何投资建议或买卖股票之依据。投资有风险，决策需谨慎。敬请投资者关注公司后续公告及相关风险披露。
English Version
Fosun Pharma Provides Large-Scale Guarantees for Subsidiaries: Aggregate Guarantees Reach RMB 21.86 Billion—Shareholders Should Monitor Leverage and Exposure Risks
Fosun Pharma Provides Large-Scale Guarantees for Subsidiaries: Aggregate Guarantees Reach RMB 21.86 Billion—Shareholders Should Monitor Leverage and Exposure Risks
Key Highlights
- On April 10, 2026, Fosun Pharma (600196.SH) disclosed a progress update on providing guarantees for several controlled subsidiaries.
- This round involves 7 subsidiaries, with a total guarantee amount of RMB 724.29 million.
- As of the announcement date, the Group’s actual external guarantee balance reaches RMB 21.86 billion, accounting for 44.86% of audited net assets at year-end 2025.
- The report highlights that some guaranteed parties have an asset-liability ratio above 70%, reflecting financial pressure and exposure risk.
- All guarantees fall within the annual shareholder meeting’s pre-approved limits and need not be re-approved by the board or shareholders.
Detailed Guarantee Arrangements
| Guaranteed Party |
Current Guarantee (RMB mn) |
Total Guarantee Balance (RMB mn) |
Counter-Guarantee |
Key Financials (2025, RMB mn) |
| Fosun Pharma Industry |
385 |
10,081.21 |
Wholly-owned, no counter-guarantee |
Total assets: 23.67bn, Net assets: 10.14bn, Net profit: 677mn |
| Fosun Health |
300 |
2,090.87 |
Counter-guarantees (equity pledges, etc.) |
Total assets: 8.81bn, Net assets: 5.04bn, Net profit: 39.9mn |
| Xuzhou Xingchen Hospital |
10 |
144.28 |
Counter-guarantee via equity pledge |
Total assets: 447mn, Net assets: 144mn, Net profit: -23.67mn |
| Tianjin Jiajia |
15 |
38.73 |
Counter-guarantee (fixed asset mortgage, etc.) |
Total assets: 201mn, Net assets: 16.37mn, Net profit: 0.36mn |
| Jinan Jianyuan |
8.8 |
20.44 |
Counter-guarantee via equity pledge |
Total assets: 25.68mn, Net assets: 20.48mn, Net profit: -17.44mn |
| Kunshan Jiajia |
5.5 |
26.13 |
Counter-guarantee via equity pledge |
Total assets: 176.94mn, Net assets: 37.82mn, Net profit: -11mn |
| Shandong Erye |
10 |
100 |
Wholly-owned, no counter-guarantee |
Total assets: 744.8mn, Net assets: 377.59mn, Net profit: 28.12mn |
Main Terms of Guarantee Agreements
- Guarantee periods: Up to 10 years for some financing arrangements, with liability lasting until three years after the debt’s maturity.
- Scope: Principal, interest, and other payables, with some guarantees structured as “maximum joint and several liability.”
- Some guarantees feature counter-guarantees (equity pledges, asset mortgages, etc.).
Investor Impact and Risk Alerts
- Large exposures may increase group risk: As of April 10, 2026, total guarantees reach RMB 21.86bn—nearly half of net assets. This sizable figure may raise the group’s overall risk profile.
- High leverage among some guaranteed parties: Some subsidiaries have liabilities exceeding 70% of assets; if their business deteriorates or they default, the parent company may be forced to take on substantial liabilities.
- Some subsidiaries are loss-making: Several guaranteed entities (e.g., Xuzhou Xingchen Hospital, Jinan Jianyuan, Kunshan Jiajia) reported losses, raising questions about their short-term repayment ability.
- Guarantee headroom remains: Current guarantees are within the RMB 35.05bn quota approved by the annual general meeting, with about RMB 27.18bn still available.
- No overdue guarantees: As of the announcement date, the group reported zero overdue guarantees.
- Board affirms risk is controllable: The board and independent directors unanimously believe the risk is relatively controllable, as all guarantees are for controlled subsidiaries and required for operations.
Investor Recommendations
- Investors should closely monitor the performance and financial health of highly leveraged and loss-making guaranteed subsidiaries. Prolonged losses or defaults could force the parent to fulfill guarantee obligations, impacting profits and cash flow.
- The large guarantee program reflects the group’s expansion and support for subsidiaries, but also raises the group’s overall risk. Investors should follow future guarantee amounts and risk management measures.
- Any further large guarantees or fulfillment of guarantee obligations could trigger share price volatility.
Disclaimer
This article is for information purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investment involves risk. Please refer to the company’s official announcements and risk disclosures for further information.
View 复星医药 Historical chart here
